기업명
강스템바이오텍
IR 일시
2017-01-09
강스템바이오텍(217730) * 주요 내용 (본 IR자료는 영문자료입니다) (1p) Business Area : Stem Cell Therapy R&D [Naive Stem Cell] (10~19p) Furestem-AD(Atopic Dermatitis)® - World's First Stem Cell Therapeutic Product for Atopic Dermatitis : Fulfilling Medical Unmet Needs - Domestic (South Korea) Strategic Plan : Goal is to launch Furestem-AD® in 2019 through conditional approval after completion of phase 2b (20~23p) Furestem-RA(Rheumatoid Arthritis)® - Stem cell therapeutic products aimed for fundamental treatment through immune modulation [Clinical Outcome] Phase 1/2a (multi-dose) Scheduled - IND Submission : 2016, Clinical Trial : 2017 to 2018 (24~26p) Furestem-CD(Crohn's Disease)® After Phase II, plan to enter the market early by receiving orphan drug designation and conditional approval -> Anticipate revenue through early approval of Furestem-CD®